Results 21 to 30 of about 5,533 (163)

Recurrent severe thrombocytopenia in critical illness complicated by hemolysis

, 2023
American Journal of Hematology, Volume 98, Issue 9, Page 1490-1496, September 2023.
Siavash Piran, Nour Alhomsi, Theodore E. Warkentin   +2 more
wiley   +1 more source

The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]

Vojnosanitetski Pregled, 2002
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko, Dinčić Dragan, Obradović Slobodan, Marković Milić, Orozović Vjekoslav   +4 more
doaj   +1 more source

Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

BMC Cardiovascular Disorders, 2017
Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández, Mario Sadaba Sagredo, Miren Telleria Arrieta, Federico Gimeno de Carlos, Elena Sanchez Lacuesta, Juan A. Bullones Ramírez, Javier Pineda Rocamora, Victoria Martin Yuste, Tamara Garcia Camarero, Mariano Larman, Jose R. Rumoroso   +10 more
doaj   +1 more source

Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study

Cardiovascular Ultrasound, 2012
Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel, Jung Christian, Otto Sylvia, Utschig Stephan, Hartmann Michael, Lehmann Thomas, Yilmaz Atilla, Pörner Tudor C, Figulla Hans R, Ferrari Markus   +9 more
doaj   +1 more source

Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience

Indian Heart Journal, 2013
Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj   +1 more source

Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis, 2020
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible
Xiaolin Zhu MD, Genmao Cao MD
doaj   +1 more source

Hypercoagulability identified in dogs with chronic enteropathy using a point‐of‐care viscoelastic assay

Journal of Small Animal Practice, EarlyView.
Objectives Thromboelastography (TEG) using the TEG 6s, a point‐of‐care viscoelastic assay, was prospectively evaluated in dogs with chronic enteropathy (CE). Additionally, the study determined whether disease activity, assessed using the Canine Chronic Enteropathy Clinical Activity Index (CCECAI), correlated with TEG 6s parameters.
S. I. Barth, S. M. DeMonaco, B. J. Conner, A. R. Wilkinson   +3 more
wiley   +1 more source

Antithrombotic use in retinal artery occlusion: A narrative review

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 4, April 2025.
Abstract Retinal artery occlusion (RAO) is a critical ophthalmic emergency with a high risk of significant visual impairment. While traditional treatment aims to promptly restore blood flow to the retina, recent research has investigated the potential benefits of anticoagulation therapy for managing this condition. This paper reviews current literature
Wan‐Yu Liu, Yun‐Hsin Tang, Yi‐Hsing Chen   +2 more
wiley   +1 more source

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

Acta Ortopédica Brasileira, 2000
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj   +1 more source

Targeting noncoding RNAs to treat atherosclerosis

British Journal of Pharmacology, Volume 182, Issue 2, Page 220-245, January 2025.
Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population.
Miron Sopić, Sandra Vladimirov, Jelena Munjas, Tijana Mitić, Ignacio Fernando Hall, Amela Jusic, Dusan Ruzic, Yvan Devaux, On behalf of AtheroNET COST Action CA21153 (https://atheronet.eu/)   +8 more
wiley   +1 more source